منابع مشابه
Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.
BACKGROUND & AIMS Efforts to develop an effective vaccine against hepatitis C virus (HCV) have been hindered by the propensity of the virus to evade host immune responses. HCV particles in serum and in cell culture associate with lipoproteins, which contribute to viral entry. Lipoprotein association has also been proposed to mediate viral evasion of the humoral immune response, though the mecha...
متن کاملHepatitis C virus and skin
Nowadays viral hepatitis is one of the most common and important causes of chronic liver disorders in the world. Extrahepatic manifestations of viral hepatitis consist a main part of the disease. The main viruses causing hepatitis include Hepatitis A, B and C viruses. Herein common skin manifestations in hepatitis C virus (HCV) are discussed. Chronic hepatitis causes skin disorders both directl...
متن کاملApolipoprotein c1 association with hepatitis C virus.
Accumulating evidence suggests that cellular lipoprotein components are involved in hepatitis C virus (HCV) morphogenesis, but the precise contribution of these components remains unclear. We investigated the involvement of apolipoprotein C1 (ApoC1) in HCV infection in the HCV pseudotyped particle system (HCVpp), in the recently developed cell culture infection model (HCVcc), and in authentic H...
متن کاملHuman apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.
UNLABELLED Hepatitis C virus (HCV) entry is a multiple-step process involving a number of host factors and hence represents a promising target for new antiviral drug development. In search of novel inhibitors of HCV infection, we found that a human apolipoprotein E (apoE) peptide, hEP, containing both a receptor binding fragment and a lipid binding fragment of apoE specifically blocked the entr...
متن کاملHepatitis C Virus and Vaccine Development
The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hepatology
سال: 2003
ISSN: 0270-9139,1527-3350
DOI: 10.1002/hep.1840380437